Navigation Links
Micromet to Present at Two Upcoming Investor Conferences
Date:2/7/2008

BETHESDA, Md., Feb. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will present at two upcoming investor conferences; one sponsored by the Biotechnology Industry Organization (BIO) and the other by Roth Capital Partners.

Dr. Itin will present at the 2008 BIO CEO and Investor Conference in New York, on Wednesday, February 13, 2008 at 2:00 pm Eastern Time (8:00 pm Central European Time). An audio webcast of Dr. Itin's remarks will be available live and accessible through Micromet's website at http://www.micromet-inc.com, as well as a replay and download of the presentation slides following the event.

Dr. Itin will also present at the Roth Capital Partners 2008 OC Growth Stock Conference in Dana Point California, on Tuesday, February 19, 2008 at 9:30 am Pacific Time.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the most advanced antibody in Micromet's product pipeline developed using the BiTE(R) antibody technology platform , is being developed in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia, and in a phase 1 clinical trial for the treatment of patients with non- Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second cl
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
6. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
7. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
8. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. Genelabs Technologies to Present at the BIO CEO & Investor Conference
10. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Scientists at USC have developed a new microscopy ... in living animals at higher-than-ever resolution. , Dubbed ... allows imaging resolutions that are an order of ... insights into the behavior of biomolecules at the ... Sept. 18 by Nature Communications , the ...
(Date:9/18/2014)... Silicon-valley Electronic Data Capture (EDC) provider ... , the latest addition to Clinovo’s CRO Partnership Program. ... (CRO) Program, Clinovo further expands its global reach to ... training, we are now able to build studies on ... can also rely on Clinovo to fully support the ...
(Date:9/18/2014)... New York, NY (PRWEB) September 18, 2014 ... has completed negotiations with Salem Realty Group and has ... and development space within the Salem Executive Complex adjacent ... cutting ceremony was held on Friday September 5th. Whitehouse ... to refit the entire space specifically for package testing. ...
(Date:9/17/2014)... Sept. 17, 2014 The global consumption of squalene ... Squalene is a natural skin-identical chemical that finds applications in ... food supplements, pharmaceuticals, and in other applications like high grade ... has a few major players and is regionally segregated. Sophim ... Liver Oil Co. Ltd. ( Japan ), SeaDragon ...
Breaking Biology Technology:Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3
... Third Quarter Highlights Recognized ... from Department of Defense (DoD) for nerve agent medical countermeasure ... profit split on worldwide sales of ST-246 and related products ... Completed 1500L commercial scale-up and first cGMP manufacturing run ...
... 8, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... today announced financial results for the third quarter of 2011. ... a net loss of $4.6 million, or $0.10 per share, ... $0.31 per share, for the third quarter of 2010. As ...
... for data-intensive biomedical and genetic research -- is ... team of researchers including Anton Nekrutenko, an associate ... State University; Kateryna Makova, an associate professor of ... Emory University, developed the new technology, which will ...
Cached Biology Technology:PharmAthene Reports Third Quarter 2011 Financial and Operating Results 2PharmAthene Reports Third Quarter 2011 Financial and Operating Results 3PharmAthene Reports Third Quarter 2011 Financial and Operating Results 4PharmAthene Reports Third Quarter 2011 Financial and Operating Results 5PharmAthene Reports Third Quarter 2011 Financial and Operating Results 6PharmAthene Reports Third Quarter 2011 Financial and Operating Results 7PharmAthene Reports Third Quarter 2011 Financial and Operating Results 8Orexigen® Therapeutics Reports Third Quarter Financial Results 2Orexigen® Therapeutics Reports Third Quarter Financial Results 3Orexigen® Therapeutics Reports Third Quarter Financial Results 4Orexigen® Therapeutics Reports Third Quarter Financial Results 5Galaxy DNA-analysis software is now available 'in the cloud' 2Galaxy DNA-analysis software is now available 'in the cloud' 3
(Date:9/17/2014)... Informatics at IMIM (Hospital del Mar Medical Research Institute) ... recently published a study in eLife showing ... in the evolution of new proteins, some of which ... Ribosomes produce proteins from the instructions found in an ... is RNA containing information for the synthesis of proteins, ...
(Date:9/17/2014)... Mich. Mutations in the human retinoblastoma protein gene ... State University scientists have turned to fruit fly eyes ... , In a paper featured on the cover ... Biological Chemistry , Michigan State University researchers provide the ... to those present in the human cancer gene, said ...
(Date:9/17/2014)... decades of decline, grasses have returned to some once-denuded ... marsh in those places seems healthy again, but a ... the marsh coastal protection remains diminished. , ... hasn,t come back," said ecologist Mark Bertness, professor of ... in the journal Biological Conservation . "The metric ...
Breaking Biology News(10 mins):Parts of genome without a known function may play a key role in the birth of new proteins 2Abnormal properties of cancer protein revealed in fly eyes 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3
... In order for a gene to create a protein, ... as messenger RNA. These RNA molecules are the instruction manuals ... how to build a protein. A few years ago, scientists ... metabolic products (metabolites) can bind to. In doing so, they ...
... New drugs that are helping fight a multi-front war on ... of Georgia researchers said. Cancer and cardiovascular disease, both ... shock protein 90 inhibitors as a treatment could become additional ... Biology Center. "I think hsp90 inhibitors may be some ...
... David L. Rimoin, MD, PhD, FACMG of Cedars-Sinai ... College of Medical Genetics Foundation (ACMGF) second annual Lifetime ... Dr. Rimoin was recognized for his decades of contributions ... and heritable disorders of connective tissue, and for helping ...
Cached Biology News:Genes under control 2New cancer therapy may fight cardiovascular disease 2Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award 2Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award 3
... The TUNEL-based assay kit provides complete ... cells for convenient detection of DNA ... sections. The incorporation of BrdU in ... biotinylated or digoxigenylated methods. Results can ...
... ergonomic microscopes are now available in digital ... DM-BA200 comes packed with Motic's patented Colour ... plug and play digital image capture head. ... a reversed quadruple nosepiece, deliver high quality ...
... The Fujifilm Life Science LAS-3000 ... technology with a simplified user interface, ... a wide range of modularities. The ... applications, and the perfect standard system ...
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
Biology Products: